107 related articles for article (PubMed ID: 31950016)
1. Two cases of anaphylaxis due to contrast media during administration of nivolumab and ipilimumab in metastatic renal cell carcinoma.
Nezu K; Katayama H; Kyan A
Int Cancer Conf J; 2020 Jan; 9(1):36-40. PubMed ID: 31950016
[TBL] [Abstract][Full Text] [Related]
2. Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma.
Iwaki T; Niimi A; Kano M; Kurokawa Y; Yoshizaki U; Nozaki K; Nomiya A; Miyazaki H; Kume H
IJU Case Rep; 2021 Jan; 4(1):32-35. PubMed ID: 33426493
[TBL] [Abstract][Full Text] [Related]
3. Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma.
Takahashi M; Takishita M; Yamazato Y; Kakinoki H; Udo K; Tobu S; Noguchi M
CEN Case Rep; 2023 May; 12(2):237-241. PubMed ID: 36402939
[TBL] [Abstract][Full Text] [Related]
4. Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report.
Motonaga A; Nakanishi S; Tanaka K; Nishida S; Izumi K; Saito S
Urol Case Rep; 2021 Sep; 38():101661. PubMed ID: 33868946
[TBL] [Abstract][Full Text] [Related]
5. A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma.
Kijima Y; Shimizu T; Kato S; Sekido E; Kano K; Toguchi M; Horiuchi T; Toma H; Iida S; Takagi T
IJU Case Rep; 2022 Mar; 5(2):126-128. PubMed ID: 35252798
[TBL] [Abstract][Full Text] [Related]
6. [A CASE OF RENAL CELL CARCINOMA WITH SMALL INTESTINE METASTASIS DURING NIVOLUMAB PLUS IPILIMUMAB].
Karibe Y; Tabei T; Hayashi H; Sugimura R; Takizawa H; Terao H; Funahashi M; Ota J; Moriyama M
Nihon Hinyokika Gakkai Zasshi; 2022; 113(3):110-114. PubMed ID: 37468276
[TBL] [Abstract][Full Text] [Related]
7. [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].
Oya M; Tajima Y; Kabu K
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1397-1404. PubMed ID: 31530779
[TBL] [Abstract][Full Text] [Related]
8. Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma.
Nishimura Y; Yamanaka K; Kato T; Hatano K; Kawashima A; Fukuhara S; Uemura M; Imamura R; Nonomura N
IJU Case Rep; 2023 Mar; 6(2):101-105. PubMed ID: 36874995
[TBL] [Abstract][Full Text] [Related]
9. [Renal Cancer Tissue after Nivolumab/Ipilimumab Combination Therapy for Metastatic Renal Cell Carcinoma].
Okuno Y; Tanaka R; Mikami K; Takeuchi T
Hinyokika Kiyo; 2020 Jan; 66(1):13-17. PubMed ID: 32028750
[TBL] [Abstract][Full Text] [Related]
10. [A case of meningoencephalitis and polyradiculoneuropathy induced by combination therapy with ipilimumab and nivolumab].
Ohno N; Sugimoto T; Giga M; Naito H; Kono T; Nomura E
Rinsho Shinkeigaku; 2021 Oct; 61(10):658-662. PubMed ID: 34565749
[TBL] [Abstract][Full Text] [Related]
11. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.
Sejima T; Masago T; Yoshida M; Nishi T; Kawabata Y; Tajima Y; Yumioka T; Honda M; Takenaka A
Int Cancer Conf J; 2021 Oct; 10(4):285-289. PubMed ID: 34567939
[TBL] [Abstract][Full Text] [Related]
12. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
Front Oncol; 2019; 9():1033. PubMed ID: 31649889
[No Abstract] [Full Text] [Related]
13. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
14. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
15. A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects.
Utsunomiya A; Oyama N; Iino S; Baba N; Chino T; Utsunomiya N; Hasegawa M
Case Rep Dermatol; 2018; 10(1):1-6. PubMed ID: 29515387
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
[TBL] [Abstract][Full Text] [Related]
17. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
18. Two cases of delayed onset of immune-related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer.
Nakai Y; Otsuka T; Inoue T; Nawa T; Hatano K; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Nishimura K
IJU Case Rep; 2021 Sep; 4(5):326-329. PubMed ID: 34497995
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report.
Nassri AB; Muenyi V; AlKhasawneh A; Ribeiro BS; Scolapio JS; Malespin M; de Melo SW
World J Gastrointest Pharmacol Ther; 2019 Jan; 10(1):29-34. PubMed ID: 30697447
[TBL] [Abstract][Full Text] [Related]
20. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.
Watanabe K; Sugiyama T; Otsuka A; Miyake H
Int Cancer Conf J; 2020 Jan; 9(1):32-35. PubMed ID: 31950015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
